Citations

Clear

3 citation(s) found for "Smith, Lauren".

Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Degnim, Amy C. , Siontis, Brittany L. , Ahmed, Safia K. , Hoskin, Tanya L. , Hieken, Tina J. , Jakub, James W. , Baum, Christian L. , Day, Courtney N. , Schrup, Sarah E. , Smith, Lauren , Carter, Jodi M. , Sae-Kho, Tiffany M. , Glazebrook, Katrina N. , Vijayasekaran, Aparna , Okuno, Scott H. , Petersen, Ivy A. , Day, Courtney , Siontis, Brittany L , Hieken, Tina J , Degnim, Amy C , Jakub, James W , Hoskin, Tanya , Carter, Jodi

Mayo Clinic

Clinical Cancer Research | May 24, 2023 | Volume: 29 | Issue: 15 | Pages: 2885-2893

10.1158/1078-0432.ccr-23-0443 | PMID 37223927 Get It

Abstract Purpose: To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment. Experimental Design: With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins. Results: A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P < 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3–44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing. Conclusions: Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.
Optimal Dose of Calcium for Treatment of Nutritional Rickets: A Randomized Controlled Trial
Thacher, Tom D. , Smith, Lauren, Isichei, Christian O., Cha, Stephen S, Pettifor, John Μ. , Fischer, Philip R. , Cha, Stephen S, Pettifor, John M , Thacher, Thomas D

Mayo Clinic

Journal of Bone and Mineral Research | June 17, 2016 | Volume: 31 | Issue: 11 | Pages: 2024-2031

10.1002/jbmr.2886 | PMID 27311415 Get It

ABSTRACT Calcium supplementation is indicated for the treatment of nutritional rickets. Our aim was to determine the optimal dose of calcium for treatment of children with rickets. Sixty-five Nigerian children with radiographically confirmed rickets were randomized to daily supplemental calcium intake of 500 mg (n = 21), 1000 mg (n = 23), or 2000 mg (n = 21). Venous blood, radiographs, and forearm areal bone density (aBMD) were obtained at baseline and at 8, 16, and 24 weeks after enrollment. The primary outcome was radiographic healing, using a 10-point radiographic severity score. The radiographic severity scores improved in all three groups, but the rate of radiographic healing (points per month) was significantly more rapid in the 1000-mg (–0.29; 95% confidence interval [CI] –0.13 to –0.45) and 2000-mg (–0.36; 95% CI –0.19 to –0.53) supplementation groups relative to the 500-mg group. The 2000-mg group did not heal more rapidly than the 1000-mg group. Of those who completed treatment for 24 weeks, 12 (67%), 20 (87%), and 14 (67%) in the 2000-mg, 1000-mg, and 500-mg groups, respectively, had achieved a radiographic score of 1.5 or less (p = 0.21). Serum alkaline phosphatase decreased and calcium increased similarly in all groups. Forearm diaphyseal aBMD improved significantly more rapidly in the 2000-mg group than in the 500-mg and 1000-mg groups (p < 0.001). Daily calcium intakes of 1000 mg or 2000 mg produced more rapid radiographic healing of rickets than 500 mg, but 2000 mg did not have greater benefit than 1000 mg. Some children require longer than 24 weeks for complete healing of nutritional rickets. © 2016 American Society for Bone and Mineral Research.
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)
Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K., Beutler, Andreas S. , Ta, Lauren E., Lafky, Jacqueline M., Wagner‐Johnston, Nina D. , Ruddy, Kathryn J. , Dakhil, Shaker R. , Staff, Nathan P. , Loprinzi, Charles L. , Smith, Ellen M L, Wagner-Johnston, Nina D., Dakhil, Shaker, Lavoie Smith, Ellen M , Grothey, Axel , Staff, Nathan P

Mayo Clinic

Journal of Clinical Oncology | August 17, 2015 | Volume: 33 | Issue: 30 | Pages: 3416-3422

10.1200/jco.2014.58.8533 | PMID 26282635 Get It

Purpose Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the current study was performed to better understand clinical parameters associated with its presentation. Methods Acute and chronic neuropathy was evaluated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Central Cancer Treatment Group, Alliance). Acute neuropathy was assessed by having patients complete daily questionnaires for 6 days with each cycle of FOLFOX. Before each dose of FOLFOX and as long as 18 months after chemotherapy cessation, chronic neurotoxicity was assessed with use of the 20-item, European Organisation for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy. Results Three hundred eight (89%) of the 346 patients had at least one symptom of acute neuropathy with the first cycle of FOLFOX; these symptoms included sensitivity to touching cold items (71%), sensitivity to swallowing cold items (71%), throat discomfort (63%), or muscle cramps (42%). Acute symptoms peaked at day 3 and improved, although they did not always resolve completely between treatments. These symptoms were about twice as severe in cycles 2 through 12 as they were in cycle 1. For chronic neurotoxicity, tingling was the most severe symptom, followed by numbness and then pain. During chemotherapy, symptoms in the hands were more prominent than they were in the feet; by 18 months, symptoms were more severe in the feet than they were in the hands. Patients with more severe acute neuropathy during the first cycle of therapy experienced more chronic sensory neurotoxicity (P < .0001). Conclusion Acute oxaliplatin-induced neuropathy symptoms do not always completely resolve between treatment cycles and are only half as severe on the first cycle as compared with subsequent cycles. There is a correlation between the severities of acute and chronic neuropathies.